Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1316 plus concurrent chemoradiotherapy in locally advanced cervical cancer
ChiCTR2600116702Phase 2Completed
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Jan 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab in Cervical Cancer (CC), sponsored by Fudan University Shanghai Cancer Center. Primary endpoints: Type, incidence and grade of drug-related adverse events of grade 3 and above and Objective Response Rate (ORR). Started Jan 2026; status: completed.
02
Drugs
adebrelimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2600116702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600116702.